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ABSTRACT 
Atherosclerosis is a cardiovascular disease where plaques made up of 
lipids in the form of cholesterol ester build up in the carotid and innominate 
arteries that supply blood to the brain. Accumulation of the plaques limit the flow 
of blood and nutrients to the brain, leading to diminished oxygen supply, 
increased oxidative stress and cell death. All these have been implicated in 
Alzheimer’s disease (AD). Alzheimer’s disease, a chronic, progressive, age 
related neurodegenerative disorder is the most common form of dementia in the 
elderly accounting for 60-80% of the cases. Clinically, Alzheimer’s disease is 
characterized by loss of memory, damage of brain tissues, and neuronal and 
synaptic loss. Pathologically, it is delineated by accumulation of amyloid beta and 
tau proteins forming senile plaques and neurofibrillary tangles respectively. 
Apolipoprotein E (ApoE) polymorphism, increased oxidative stress and products 
of lipid peroxidation are associated with atherosclerosis and Alzheimer’s disease. 
ApoE is a glycosylated protein that mediates plasma lipoprotein metabolism. 
ApoE isoforms have differential effect on amyloid beta aggregation and 
clearance, thus playing an important role in Alzheimer’s pathology. Serum 
paraoxonase 1 (PON1) is a lipoprotein associated antioxidant enzyme that 
prevents lipid peroxidation. S100B protein is a plasma biomarker, altered 
expression of which has been implied in AD. We propose the hypothesis that 
combined deficiencies in apolipoprotein E and antioxidant defense (established 
by the lack of PON1), together with dyslipidemia and development of carotid 
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atherosclerosis in aging mice would reflect Alzheimer’s pathology. The brains of 
young and old ApoE-PON1 double knockout (DKO) mice and control C57BL/6J 
mice were harvested. Atherosclerotic lesions were quantified by Image J. RNA 
was isolated, cDNA was synthesized and quantitative RT-PCR was performed to 
detect mRNA levels of S100B. Blood levels of S100B protein was measured by 
ELISA. Brain tissues were stained with Hematoxylin and Eosin stain and 4G8 
immunostain to detect histopathological changes. The blood brain barrier (BBB) 
is altered in AD resulting in increased permeability and vascular dysfunction. The 
vascular permeability of BBB was analyzed by Evans Blue Dye (EBD) assay. 
The results showed that the older DKO mice had severe carotid atherosclerosis, 
increased levels of serum S100B protein and elevated mRNA levels of S100B. 
Histological examination showed the presence of characteristic hallmarks of AD. 
The leakage of EBD into brain parenchyma indicated disruption of BBB. The 
results suggest that diminished blood flow and nutrient supply to the brain due to 
atherosclerosis and increased oxidative stress might contribute to Alzheimer’s 
pathology. We suggest that older ApoE-PON1 DKO mice may serve as a model 
of Alzheimer’s disease and prevention of atherosclerosis might promote 
regression of Alzheimer’s disease. 
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CHAPTER 1: INTRODUCTION 
1.1 Atherosclerosis 
Atherosclerosis represents a major form of cardiovascular disease where 
plaques build up in the arteries that supply blood to the brain. These arteries 
include carotid and innominate arteries. Plaques made up of lipids in the form of 
cholesterol ester accumulates and narrows the arteries. Such atherosclerotic 
manifestation results in reduced supply of blood and nutrients to the brain, which 
leads to diminished oxygen supply (Kim et al. 2009), increased oxidative stress 
and cell death. This has been implicated in neurological diseases such as 
Alzheimer’s disease (Dantoine et al. 2002, Cervellati et al. 2015, Irizarry 2004, 
Menini et al. 2014). 
1.2 Rationale 
There are a number of animal models to study atherosclerosis, of which 
two models have gained importance. They are the low density lipoprotein 
receptor (LDLR) knockout mice and the Apolipoprotein E (ApoE) knockout mice. 
These mice are used to study atherosclerosis when they are 4-24 weeks old. In 
our laboratory, we superposed Paraoxonase 1 (PON1) knockout in LDLR 
knockout and ApoE knockout mice. Lack of PON1 is suggested to increase 
oxidative stress. Our studies (RO1-HL088397-Parthasarathy-Novel Mechanisms 
by which Aspirin might protect against Atherosclerosis and RO1-HL123283-
Parthasarathy-Role of Aldehyde oxidation in Atherosclerosis) have shown that 
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over time older (14 months old) ApoE-PON1 double knockout (DKO) mice 
developed increased plasma lipids and severe carotid atherosclerosis, with 70-
80% stenosis in the carotid and innominate arteries, even on normal chow diet. 
 
Figure 1: Atherosclerotic lesions in animal models under study. 
The 14 months old C57BL/6J mice did not have any lesions (a); the 4 months old 
ApoE-PON1 DKO mice did not have any lesions (b); the 14 months old ApoE-
PON1 DKO mice had severe atherosclerotic lesions (c); the 14 months old 
LDLR-PON1 DKO mice had atherosclerotic lesions (d), but to a lesser extent 
compared to age matched ApoE-PON1 DKO mice. 
The younger (4 months old) animals with the same genetic background 
and the control C57BL/6J strain did not show any occlusion in the carotid 
arteries. The older LDLR-PON1 DKO mice had a lesser extent of atherosclerotic 
lesions than the age matched ApoE-PON1 DKO mice. While maintaining these 
animal colonies, we observed that the older ApoE-PON1 DKO mice suffered 
from seizures, neck and paw edema, and gait imbalance indicating that these 
animals might have other vasculature related neurological problems. Studies 
indicate that Alzheimer’s disease patients, at later stages of the disease have 6-
10 folds more risk of having seizures (Pandis and Scarmeas 2012). From these 
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observations, we suggest that older ApoE-PON1 DKO mice, with lesions in 
carotid and innominate arteries, that is, atherosclerosis, could develop 
neurological problems such as Alzheimer’s disease.  
1.3 Alzheimer’s disease 
Alzheimer’s disease (AD), the most common form of dementia affecting 
older people, mostly over the age of 65 years (MacLeod et al. 2015, Liu et al. 
2013, Rohn 2013) accounts for 75% of the cases of dementia (MacLeod et al. 
2015, Sadigh-Eteghad et al. 2014, Qiu et al. 2009). It is a chronic, progressive, 
age related neurodegenerative disorder (Liu et al. 2013, Butterfield et al. 2013, 
Dubravka et al. 2001, Rohn 2013). Most cases of AD are sporadic. 
Approximately 5% have genetic disposition (familial) because of polymorphisms 
that affect amyloid beta secretion (MacLeod et al. 2015, Dubravka et al. 2001, 
Rohn 2013, Qiu et al. 2009). Clinically, AD is characterized by loss of episodic 
memory (Kim et al. 2009, Butterfield et al. 2013, Dubravka et al. 2001), cognitive 
and executive functions such as vocabulary and acumen (MacLeod et al. 2015, 
Kim et al. 2009, Dubravka et al. 2001, Sadigh-Eteghad et al. 2014) and depletion 
of neuronal and synaptic connections (MacLeod et al. 2015, Kim et al. 2009, 
Butterfield et al. 2013). AD is not part of normal aging (CDC). The disease 
initiates about 20 years before there are any apparent symptoms (Mikula et al. 
2014, Rohn 2013, Sadigh-Eteghad et al. 2014). The symptoms of AD appear 
after the age of 60 years and the risk of disease advancement increases with age 
(Dubravka et al. 2001, CDC). So, older age is one of the greatest risk factors for 
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AD (CDC, www.alz.org, Qiu et al. 2009, Rohn 2013) affecting 13% of people over 
the age of 65 years and 45% of people over the age of 85 years (Liu et al. 2013, 
Hauser et al. 2013). Unfortunately, the onset of AD cannot be delayed, paused or 
restrained (www.alz.org). Oxidative stress and neuroinflammation have also 
been implicated in AD (Kim et al. 2009, Cervellati et al. 2015, Cirillo et al. 2015). 
1.4 Epidemiology of Alzheimer’s disease 
At present, over 35 million people worldwide are affected by AD and its 
ascendancy doubles every 5 years in patients over the age of 60 years (Mikula et 
al. 2014, Sadigh-Eteghad et al. 2014, Qiu et al. 2009, CDC). It is the sixth leading 
cause of death in the United States (www.alz.org, CDC, Rohn 2013). More than 
5 million Americans aged 65 years or more suffered from AD in 2013 
(www.alz.org, CDC, Butterfield et al. 2013, Rohn 2013) and this number is 
predicted to inflate to 14 million by 2050 which is almost a 3-4-fold increase 
(www.alz.org, CDC). The healthcare cost of AD is estimated to be $172 billion a 
year (Reitz et al. 2014).  
1.5 Characteristics of Alzheimer’s disease 
Pathologically, AD is delineated by the aggregation of two proteins, the 
amyloid beta or Aβ and tau. The amyloid beta forms senile plaques surrounded 
by glial cells and damaged neurons outside and around nerve tissues of the brain 
(MacLeod et al. 2015, Kim et al. 2009, Paulson et al. 2008, Serrano-Pozo et al. 
2011, Perl 2010), and  tau proteins are associated with microtubules, which 
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forms neurofibrillary tangles (NFT) within nerve cells or neurons, especially in the 
hippocampus (MacLeod et al. 2015, Kim et al. 2009, Paulson et al. 2008, 
Lasagna-Reeves et al. 2012, Serrano-Pozo et al. 2011). The NFTs are formed 
due to hyperphosphorylation of twisted filaments of tau (Paulson et al. 2008, 
Serrano-Pozo et al. 2011). Other characteristics of AD include diffuse and 
neuritic plaques (Reitz et al. 2014), ventricular enlargement and degeneration 
(MacLeod et al. 2015). 
Histological hallmarks, shown in research with other animal models of AD 
encompass neuronal and synaptic loss, neuritic dystrophy, loss of pyramidal cells 
(http://www.scholarpedia.org/article/Pyramidal_neuron)  in the cornu ammonis 
(CA) region, loss of granule cells in the dentate gyrus of hippocampus, 
granulovacuolar degeneration (Paulson et al. 2008, Serrano-Pozo et al. 2011, 
Perl 2010), presence of deeply stained nuclei, neuropil threads (Serrano-Pozo et 
al. 2011, Dong et al. 2012), and eosinophilic rod-like bodies known as Hirano 
bodies (Serrano-Pozo et al. 2011, Perl 2010). Cortical dysfunction and dystrophic 
neurites are also noticed (Serrano-Pozo et al. 2011). 
Hippocampus is the main area of the brain affected by AD and the 
histological markers are primarily seen in this region. It is located under the 
cerebral cortex (http://neuroscience.uth.tmc.edu/s4/chapter05.html) and plays a 
central role in brain functions such as learning, short and long term memory and 
spatial memory (Jonas et al. 2015). The hippocampus is divided into two major 
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parts, the cornu ammonis (CA) region and the dentate gyrus (DG) (Hartley et al. 
2014). The CA region is subdivided into the CA1, CA2, CA3 and CA4 regions 
(Hartley et al. 2014). The preeminent types of cells in CA and DG areas are the 
pyramidal and granule cells respectively (Amaral et al. 2007).  
Pyramidal cells have a triangular shaped body called soma, a single axon 
that extends towards the grey matter and thick, multiple, branching dendrites 
extending towards the cortex 
(http://www.scholarpedia.org/article/Pyramidal_neuron, Elston 2003). Pyramidal 
cells send nerve impulses to cerebral cortex, hippocampus and amygdala parts 
of the brain and helps in cognitive functions 
(http://www.scholarpedia.org/article/Pyramidal_neuron). The pyramidal cells of 
CA1 region are susceptible to neurodegeneration.  
The CA4 region underlies the dentate gyrus. Neurogenesis occurs at the 
DG region and new memories are formed (Amaral et al. 2007, Jonas et al. 2015, 
Lopez-Rojas et al. 2016). Granule cells are formed in the subgranular zone of 
DG (Lopez-Rojas et al. 2016) and they receive excitatory neuronal input from the 
entorhinal cortex and send excitatory neuronal output to CA3 region (Amaral et 
al. 2007, Jonas et al. 2015). Loss of granule cells in the DG result in memory 
loss. 
Neuropil threads are found with NFTs that comprise of 
hyperphosphorylated tau and ubiquitin in the dendrites (Lasagna-Reeves et al. 
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2012, Serrano-Pozo et al. 2011, Dubravka et al. 2001). They are segments of 
axons, dendrites and presynaptic terminals (Serrano-Pozo et al. 2011, Dubravka 
et al. 2001). In the neuropil they are present as argentophilic circuit of paired 
helical fibers (Dubravka et al. 2001). 
Granulovacuolar degeneration (GVD) are cytoplasmic lesions in the 
pyramidal cells of hippocampus (Serrano-Pozo et al. 2011, Dubravka et al. 
2001), between the CA1 and CA2 regions (Perl 2010). They are argentophilic 
double membraned vacuolar structures within the neurons with a granular 
basophilic core (Serrano-Pozo et al. 2011, Perl 2010, Dubravka et al. 2001). 
Hirano bodies are eosinophilic inclusions surrounding the neurons in the 
CA1 region of hippocampus (Serrano-Pozo et al. 2011, Perl 2010, Dubravka et 
al. 2001). Hirano bodies are rodlike structures composed of braided parallel 
fibers (Serrano-Pozo et al. 2011, Perl 2010, Dubravka et al. 2001) and are 
composed of actin and actin associated proteins in neurons (Maselli et al. 2003).  
Due to altered chromatin conformation, which are pathological markers of 
AD (Crapper et al. 1979), deeply stained nuclei are identified in AD brain. They 
are small, deeply stained irregular nuclei due to fragmentation and contain 
chromatin granules.  
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1.6 Parts of brain affected by Alzheimer’s disease 
The parts of the brain that are affected by Alzheimer’s disease are 
hippocampus, cerebral cortex and olfactory lobes (MacLeod et al. 2015, 
Dubravka et al., Sadigh-Eteghad et al. 2014). Morphologically in AD brain, the 
cerebral cortex and hippocampus are shrunken due to death of neurons and loss 
of connection between them and the ventricles are amplified due to neuronal 
tissue degeneration (MacLeod et al. 2015, Perl 2010) and cerebrospinal fluid 
accumulation. 
1.7 Stages and Symptoms of Alzheimer’s Disease 
AD develops in seven stages (www.webmd.com, www.alzheimers.net) as 
shown in Figure 2. These stages are: Pre-clinical, Very Mild Cognitive decline, 
Mild Cognitive Impairment (MCI), Moderate decline, Moderately Severe decline, 
Severe decline and Very Severe decline (Butterfield et al. 2013, Rohn 2013, 
www.webmd.com, www.alzheimers.net). AD can be classified as early onset AD 
(<65 years) (Butterfield et al. 2013, Reitz et al. 2014, www.hopkinsmedicine.org) 
and late onset AD (>65 years) based on the age of onset (Liu et al. 2013, 
Butterfield et al. 2013, Reitz et al. 2014).  
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Figure 2: The seven stages of Alzheimer’s disease progression. 
The seven stages in which Alzheimer’s disease develops are Pre-clinical, Very 
Mild Cognitive decline, Mild Cognitive Impairment (MCI), Moderate decline, 
Moderately Severe decline, Severe decline and Very Severe decline. 
Memory impairment, incompetence to learn, alterations in personality and 
behavior, judgmental errors, ineptitude to communicate, hardship to perform 
normal tasks, inadequacy in intellect and aptitude are crucial symptoms of AD 
that result in abatement of the quality of life and longevity (Sadigh-Eteghad et al. 
2014, Rohn 2013, www.healthline.com, www.hopkinsmedicine.org). Early onset 
AD is indicated by failure to remembering recently acquired knowledge or task, 
dates, time of year and places, issues with vision and speech, problems with 
decision making, regularly losing things, enquiring about the same thing 
repeatedly and inability to backtrack (Rohn 2013, www.healthline.com, 
www.hopkinsmedicine.org, 
http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp). Symptoms of 
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late onset AD encompass severe loss of memory, diminished language and 
communication proficiency, minimal motion, inability to respond, insensitivity, 
difficulty in swallowing (Dubravka et al. 2001, www.curealz.org, 
www.alz.org/alzheimers_disease_stages_of_alzheimers.asp, 
www.hopkinsmedicine.org, www.webmd.com/alzheimers/guide/understanding-
alzheimers-disease-symptoms ). Symptoms also include confusion 
(www.webmd.com/alzheimers/guide/understanding-alzheimers-disease-
symptoms, www.alz.org/alzheimers_disease_stages_of_alzheimers.asp), 
changes in mood (www.hopkinsmedicine.org), and severe weight loss (Dubravka 
et al. 2001). 
1.8 Risk factors of Alzheimer’s disease 
The definite etiology of AD is unidentified. Both genetic and non-genetic 
factors are implicated in the risk of developing AD (Kim et al. 2009, Menini et al. 
2014, Rohn 2013, Qiu et al. 2009, Reitz et al. 2014). Non-genetic factors 
incorporate metabolic and environmental factors (Kim et al. 2009, Rohn 2013, 
Qiu et al. 2009, Reitz et al. 2014), which encompass cerebrovascular disease, 
elevated blood pressure, type 2 diabetes, increased body weight, plasma lipid 
levels, metabolic syndrome such as hypercholesterolaemia, 
hyperhomocysteinaemia, smoking, dyslipidemia and traumatic brain injury (Qiu et 
al. 2009, Reitz et al. 2014, Breteler et al. 2000, Iadecola et al. 2004). Various risk 
factors contributing to AD are shown in Table 1 (Rohn 2013, Qiu et al. 2009, 
Reitz et al. 2014, Breteler et al. 2000, Iadecola et al. 2004).  
11 
 
Table 1: Various risk factors affecting Alzheimer’s disease.  
APP: Amyloid Precursor Protein, PSEN: Presenilin, ApoE: Apolipoprotein E, 
BIN1: Bridging Integrator 1, CLU: Clusterin, ABC: ATP Binding Cassette, A7: 
Annexin 7, CR1: Complement Receptor 1, PICALM: Phosphatidylinositol Binding 
Clathrin Assembly Protein, A2M: Alpha-2-Macroglobulin, SORL1: Sortilin-related 
receptor gene, TREM2: Triggering receptor expressed on myeloid cells 2. 
 
 
1.9 Atherosclerosis and Alzheimer’s disease 
Atherosclerosis and AD are two of the most crucial threats to public 
health. Atherosclerosis of cerebral arteries is one of the major risk factors 
associated with the onset and advancement of Alzheimer’s disease (Gupta et al. 
2015, Scacchi et al. 2003, Breteler et al. 2000). Clinical, epidemiological, 
pathological and experimental evidence suggest that atherosclerosis and AD are 
associated (Bell et al. 2009, Gupta et al. 2015) and collectively affect brain’s 
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structure and functions, as well as amyloid beta (Aβ) production and clearance 
(Gupta et al. 2015). Data from Cardiovascular Health Study demonstrated the 
risk of developing cardiovascular diseases such as atherosclerosis with AD (Qiu 
et al. 2009). Blockage in carotid and innominate arteries due to atherosclerosis 
alters perfusion of oxygen to the brain by diminishing the flow of blood and 
nutrients. This enhances the activities of β and γ secretase, which forms more 
Aβ, contributing to Alzheimer’s pathology. Increased Aβ, in turn leads to 
vasoconstriction of arteries and reduced vasodilation (Gupta et al. 2015). The 
diminished blood flow also causes intermittent ischemia and reperfusion that 
would deprive nutrients and induce cell death. Ischemia augments AD (Iadecola 
et al. 2004). Atherosclerosis and AD also have common risk factors, such as 
diabetes, hypercholesterolemia and aging (Gupta et al. 2015, Austin et al. 2010, 
Iadecola et al. 2004). 
1.10 Biomarkers of Alzheimer’s disease 
There is no definitive ante-mortem diagnostic test for AD. Precise 
diagnosis can be done by examining the histological markers in the brain 
specimen (Perl 2010). Diagnosis is based on core clinical and clinical research 
as drugs that can arrest the disease furtherance are unavailable (MacLeod et al. 
2015). Core clinical diagnosis is not reliable because the pathology of AD is 
concealed within the brain (Butterfield et al. 2013). Diagnosis by clinical research 
includes biomarkers. Biomarkers or biological markers are aspects or 
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components in an organism that are inspected squarely and analyzed (Ahmed et 
al. 2014). They usually indicate the normality of an entity or pathogenicity of a 
disease and also points out its response to therapies (Ahmed et al. 2014, 
Sadigh-Eteghad et al. 2014, Sen et al. 2007). Biomarkers determine the risk of a 
disease and endow diagnosis (Reitz et al. 2014). Characteristics of an ideal 
biomarker include stability, sensitivity, specificity, and reproducibility (Ahmed et 
al. 2014, Sen et al. 2007). A biomarker should also be rapid and non-invasive 
(Irizarry 2004). A number of biomarkers are probed for the diagnosis of 
Alzheimer’s disease. The identification of proper biomarkers for AD is essential to 
differentiate it from other forms of dementia. Different types of AD biomarkers 
based on their classification are depicted in Table 2.  
Table 2: Alzheimer’s disease biomarkers 
CRP: C-Reactive Protein, TNF: Tumor Necrosis Factor, IL: Interleukin, SOD: 
Superoxide Dismutase, PON: Paraoxonase, APP: Amyloid Precursor protein, 
ApoE: Apolipoprotein E, TOMM40: Translocase of Outer Mitochondrial 
membrane 40, Aβ: Amyloid beta, ICAM: Intercellular adhesion Molecule, VCAM: 
Vascular Cell Adhesion Molecule. 
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For this study, focus will mainly be on S100B and Amyloid beta protein. 
1.10.1 S100B 
S100B is a calcium-binding brain specific protein (Lam et al. 2013, Mikula 
et al. 2014, Sen et al. 2007). It belongs to the S100 protein family (Mikula et al. 
2014), which are present in the cytoplasm and nucleus of a number of cells and 
plays an important role in cellular growth, proliferation and differentiation, 
progression of cell cycle, signal transduction, calcium homeostasis and structure 
and function of cytoskeleton (Lam et al. 2013, Sen et al. 2007). In the central 
nervous system, S100B is produced mainly in the Schwann cells and astroglial 
cells (Lam et al. 2013, Mikula et al. 2014, Sen et al. 2007). It is an astrocytic 
cytokine and acts as a plasma biomarker for Alzheimer’s disease (Peskind et al. 
2001, Mikula et al. 2014, Sen et al. 2007). S100B can be both neurotrophic and 
neurotoxic based on its concentration (Lam et al. 2013, Mikula et al. 2014). At 
low concentrations, S100B abets survival, outgrowth and extension of neurons, 
functioning as a neurotrophic factor (Peskind et al. 2001, Lam et al. 2013, Mikula 
et al. 2014, Cirillo et al. 2015, Sen et al. 2007). In neurons and neurites, β 
amyloid precursor protein (βAPP) is generated by S100B (Peskind et al. 2001). 
S100B is composed of 92 amino acids (Guo et al. 2013) and exist in cells as a 21 
kDa homodimer (Lam et al. 2013). S100B levels increase due to damage in 
nervous system, inducing inflammation and apoptosis in neurons, thereby being 
neurotoxic (Lam et al. 2013, Cirillo et al. 2015). Neurodegenerative diseases 
such as Alzheimer’s, cerebrovascular diseases and traumatic brain injuries have 
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elevated S100B levels (Lam et al. 2013, Mikula et al. 2014, Peskind et al. 2001, 
Sen et al. 2007). Alzheimer’s patients have higher S100B level in areas of brain 
with more neuritic plaques (Lam et al. 2013, Mikula et al. 2014). Increased 
S100B level is due to cell stress and neuroinflammation, which is associated with 
AD (Lam et al. 2013, Cirillo et al. 2015). S100B is overexpressed in activated 
astrocytes and forms diffused Aβ deposits, dystrophic neurites leading to 
apoptosis, thus contributing to neurotoxicity (Peskind et al. 2001, Lam et al. 
2013, Mikula et al. 2014, Sen et al. 2007). There are epidemiologic and 
experimental evidence that implicates the role of S100B in Alzheimer’s (Peskind 
et al. 2001, Sen et al. 2007). Increased level of S100B in serum is an indication 
of blood brain barrier (BBB) disruption (Lam et al. 2013). 
1.10.2 Amyloid beta plaques 
Amyloid beta or Aβ plaques are one of the most important 
pathophysiological features of AD (Irizarry 2004, Sadigh-Eteghad et al. 2014). Aβ 
is a 4kDa protein that plays a major role in the commencement and development 
of the disease (MacLeod et al. 2015, Kim et al. 2009, Butterfield et al. 2013, 
Sadigh-Eteghad et al. 2014).  Aβ acts as a plasma and cerebrospinal fluid (CSF) 
biomarker for AD (Irizarry 2004). Proteolytic cleavage of Amyloid Precursor 
Protein (APP) by β and γ secretases generates Aβ (MacLeod et al. 2015, Kim et 
al. 2009, Butterfield et al. 2013, Sadigh-Eteghad et al. 2014). APP is a type 1 
single-pass transmembrane protein (MacLeod et al. 2015, Butterfield et al. 2013, 
Sadigh-Eteghad et al. 2014, O’Brien et al. 2011) found in many human tissues 
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like heart, skin, liver and lung (MacLeod et al. 2015). In the central nervous 
system (CNS) it is concentrated in the dendrites, cell bodies, axons and 
synapses of neurons (MacLeod et al. 2015, Kim et al. 2009, O’Brien et al. 2011). 
APP is not neurotoxic and functions in cellular and neurite growth (MacLeod et 
al. 2015, Butterfield et al. 2013, O’Brien et al. 2011), formation of synapse, 
neuronal protein transport and neural plasticity. APP is cleaved at N and C 
terminals by β and γ secretases respectively (MacLeod et al. 2015). α secretase, 
on the other hand, furcate APP within the Aβ sequence generating incomplete 
Aβ fragments (MacLeod et al. 2015). Other proteins formed are α-synuclein, 
ubiquitin, apolipoprotein E, presenilins, and alpha antichymotrypsin. Different 
isoforms of Aβ are formed due to APP cleavage by β and γ secretases that 
agglomerate to form plaques (MacLeod et al. 2015, Sadigh-Eteghad et al. 2014, 
Rohn 2013). The most common isoforms of Aβ are 40 and 42 amino acids long 
Aβ40 and Aβ42 respectively differing at the C-terminal (MacLeod et al. 2015, 
Irizarry 2004). The amount of Aβ40 is more (MacLeod et al. 2015, Kim et al. 
2009, Butterfield et al. 2013), however Aβ42 is toxic and is more in AD brain 
(Butterfield et al. 2013, Irizarry 2004) and susceptible to accumulation (MacLeod 
et al. 2015, Butterfield et al. 2013). Elevated soluble Aβ oligomer levels cause 
synaptic deterioration and neurodegeneration (MacLeod et al. 2015, Liu et al. 
2013, Serrano-Pozo et al. 2011). Based on pathological, genetic and functional 
studies, it is postulated that Aβ plaques accumulate in the brain because of 
inequality in its production and disposition from brain during aging (MacLeod et 
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al. 2015, Bell et al. 2009, Sadigh-Eteghad et al. 2014, Liu et al. 2013). Impaired 
degradation, removal of Aβ from brain by cellular uptake or transport through 
blood brain barrier might regulate sporadic AD (Kim et al. 2009, Bell et al. 
2009).  Aβ is generated by all cells, mostly by neurons (MacLeod et al. 2015, 
Kim et al. 2009). Under certain conditions, Aβ, which is synthesized in normal 
individuals aggregate into β sheets forming oligomers and fibrils which 
accumulate extracellularly to form toxic senile plaques (MacLeod et al. 2015, 
Liu et al. 2013, Sadigh-Eteghad et al. 2014, Rohn 2013,) resulting in neuronal 
dysfunction (MacLeod et al. 2015, Sadigh-Eteghad et al. 2014, Rohn 2013), 
synaptic injury and hyperphosphorylation of tau forming NFTs, thus contributing 
to Alzheimer’s pathology (MacLeod et al. 2015, Liu et al. 2013, Rohn 2013).  
1.11 Apolipoprotein E 
Association between genes and single nucleotide polymorphisms (SNP) 
(Kim et al. 2009) with the risk of developing AD have been noted. Autosomal 
dominant mutations in three genes, amyloid precursor protein (APP), presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) have been implicated in early onset AD (Liu 
et al. 2013, Irizarry 2004, Rohn 2013, Reitz et al. 2014). Apolipoprotein E 
polymorphism has been implicated in late onset AD and is of significant 
importance (Liu et al. 2013, Choi et al. 2004, O’Brien et al. 2011). Apolipoprotein 
E is a 34kDa glycosylated protein consisting of 299 amino acids (Kim et al. 2009, 
Liu et al. 2013, Holtzman et al. 2000, Hauser et al. 2013, Rohn 2013). In the 
peripheral tissues, it is primarily synthesized in the liver and macrophages and 
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helps in cholesterol metabolism (Kim et al. 2009, Liu et al. 2013, Holtzman et al. 
2000, Hauser et al. 2013). In the CNS it is also expressed in the brain by 
neurons, astrocytes and microglia (Kim et al. 2009, Liu et al. 2013, Hauser et al. 
2013, Rohn 2013). ApoE binds lipids (Reitz et al. 2014) plays an important role in 
neuronal function (Hauser et al. 2013) and carries cholesterol in brain by ApoE 
receptors that results in transport of lipids, synaptogenesis, synaptic plasticity 
and repair of damages in the brain (Liu et al. 2013, Rohn 2013, Bell et al. 2009). 
Diminished ApoE functions results in oxidative stress, changes in neuronal 
functions and synaptic loss (Choi et al. 2004). Epidemiological studies show a 
link between Apolipoprotein E alleles and Alzheimer’s disease (Kim et al. 2009, 
Holtzman et al. 2000). Human ApoE, encoded by ApoE genes is polymorphic 
with three isoforms: ApoE2, ApoE3 and ApoE4, which differ by substitution of a 
single amino acid cysteine by arginine at position 112 and 158 (Kim et al. 2009, 
Holtzman et al. 2000, Choi et al. 2004). ApoE2 allele abates the risk of 
development of AD, hence being protective (Kim et al. 2009, Holtzman et al. 
2000, Hauser et al. 2013, Rohn 2013, Bell et al. 2009), while ApoE3 allele does 
not influence one’s risk of developing AD (Hauser et al. 2013, Rohn 2013). 
ApoE4 variant increases the risk of AD and has been indicated to be the largest 
known genetic risk factor for late onset Alzheimer’s disease (Hauser et al. 2013, 
Rohn 2013, Kim et al. 2009, Holtzman et al. 2000, Choi et al. 2004). Table 3 
shows the three major isoforms of Apolipoprotein E. 
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Table 3: Apolipoprotein E allele sequence. 
The three major isoforms of ApoE depicting the change in allele sequence, 
shown in italics. 
ApoE:      Lskelqaaqa rlgadmedvr grlvqyrgev qamlgqstee lrvrlas         
ApoE2:    Vcgrlvqyrg  evqamlgqst eelrvrlash lrklrkrllr dadalqkc    
ApoE3:    Vcgrlvqyrg  evqamlgqst eelrvrlash lrklrkrllr dadalqkr 
ApoE4:    Vrgrlvqyrg  evqamlgqst eelrvrlash lrklrkrllr dadalqkr 
AD develops due to Aβ deposition in the brain because of ApoE4 allele 
(Kim et al. 2009, Holtzman et al. 2000, O’Brien et al. 2011).  Aβ peptides are 
formed at normal levels in AD patients, but are not transported or cleared from 
the brain to blood due to its association with ApoE4 (Sadigh-Eteghad et al. 2014, 
Liu et al. 2013). This increased level of Aβ leads to loss of synaptic function and 
neuronal network, ultimately leading to loss of cognitive functions. Deposition of 
Aβ forms plaques that result in death of neurons. Typically, ApoE forms high-
density lipoprotein (HDL) (Kim et al. 2009, Holtzman et al. 2000, O’Brien et al. 
2011), which proteolytically degrades Aβ peptides. However, due to mutated 
ApoE gene, this degradation does not happen, leading to the deposition of Aβ 
peptides. Evidences show that ApoE4 plays an important role in the metabolism 
of APP by increasing its cleavage, thereby elevating Aβ production (Kim et al. 
2009, Austin et al. 2010). ApoE and Aβ interact with each other and impacts the 
clearance of Aβ from the brain by uptake via cells or through the blood brain 
barrier (Kim et al. 2009, Liu et al. 2013, Hauser et al. 2013, Bell et al. 2009). 
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There are differences in the structures and functions of different isoforms of 
ApoE that impact the ApoE- Aβ interaction leading to neurodegeneration (Kim et 
al. 2009, Liu et al. 2013, Hauser et al. 2013). Due to mutation of ApoE, the 
transport of Aβ bound to ApoE4 is hindered (Kim et al. 2009, Bell et al. 2009). 
Also, the predisposition of ApoE4 to undergo cleavage generating neurotoxic N 
and C terminal fragments leads to its loss of function and impairs its binding with 
Aβ (Rohn 2013). ApoE4 is correlated with high LDL levels, hyperlipidaemia or 
hypercholesterolemia and therefore impacts cardiovascular diseases such as 
atherosclerosis (Kim et al. 2009, Liu et al. 2013). Therefore, formation of ApoE4, 
its proneness to cleavage resulting in its inability to transport cholesterol and 
clear amyloid beta may justify it being a risk factor for AD (Rohn 2013). 
1.12 Paraoxonase 1 
Increased oxidative stress (Dantoine et al. 2002, Butterfield et al. 2013, 
Cervellati et al. 2015, Irizarry 2004, Menini et al. 2014), decreased antioxidant 
content and antioxidant enzyme activity (Butterfield et al. 2013) have been noted 
in Alzheimer’s brain. Defective paraoxonase activity leads to the development of 
diseases associated with oxidative stress and lipid peroxidation (Cervellati et al. 
2015). Paraoxonase, an esterase (Dantoine et al. 2002, Menini et al. 2014, 
Litvinov et al. 2012) present with high-density lipoprotein (HDL) (Scacchi et al. 
2003, Cervellati et al. 2015, Menini et al. 2014) imparts antioxidant and anti-
inflammatory competence to the particle (Menini et al. 2014, Litvinov et al. 2012). 
PON reduces the peroxidation of LDL (Dantoine et al. 2002, Cellini et al. 2006, 
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Wingo et al. 2012) which induces atherogenesis and dementia (Cellini et al. 
2006). It is an antioxidant enzyme and plays a significant role in atherosclerosis 
by providing protection against the disease as shown in epidemiological studies 
(Scacchi et al. 2003, Wingo et al. 2012, Menini et al. 2014, Litvinov et al. 2012). It 
modulates paraoxon hydrolysis (Scacchi et al. 2003, Menini et al. 2014). 
Mutation in the PON gene may increase the risk of developing AD, the strongest 
association being PON1 (Cellini et al. 2006, Wingo et al. 2012, Menini et al. 
2014). There are 3 genetic variants of PON gene: PON1, PON2, PON3 (Cellini et 
al. 2006, Scacchi et al. 2003, Litvinov et al. 2012). PON1 is primarily produced in 
the liver with HDL (Menini et al. 2014, Litvinov et al. 2012) and is implicated in 
causing neurodegenerative diseases, such as AD (Wingo et al. 2012). 
Diminished PON1 activity is linked to risk of causing cardiovascular diseases and 
Late Onset of AD or LOAD (Cellini et al. 2006, Cervellati et al. 2015, Menini et al. 
2014). PON1 gene might be competent to treat AD as it can respond to 
cholinesterase inhibitors (Cellini et al. 2006). Thus, PON, lipid peroxidation, 
atherosclerosis and AD are closely related (Cellini et al. 2006, Wingo et al. 2012).  
PON2 is an antioxidant and anti-inflammatory enzyme present in various 
cells including heart, lung, kidney, liver, small intestine, pancreas, macrophages 
and brain. In the brain, it is found in astrocytes. Increase in PON2 expression 
reduces lesions formed in atherosclerosis. PON2 polymorphism increases the 
risk of developing AD (Costa et al. 2014).   
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1.13 Blood Brain Barrier and Evans Blue Dye 
Blood brain barrier (BBB) is a vascular system partitioning blood in 
circulation and CSF in the brain (Jaffer et al. 2013, Manaenko et al. 2011). It is 
made up of endothelial cell tight junctions, glial cells and basal lamina (Jaffer et 
al. 2013, Manaenko et al. 2011, Iadecola et al. 2004). BBB is permeable to 
oxygen, carbon dioxide, glucose, water and ions and inhibits the flow of proteins, 
bacteria, toxins, drugs and solutes between brain and blood (Bell et al. 2009, 
Montagne et al. 2015, Marques et al. 2013). Disarticulation of this barrier 
increases permeability of neurotoxic proteins (Montagne et al. 2015) and other 
proteins present in the serum (Rákos et al. 2007) resulting in vascular 
dysfunction, as seen in several diseases, such as brain tumors, infection in CNS, 
epilepsy, and neurological diseases such as Alzheimer’s (Jaffer et al. 2013, 
Montagne et al. 2015, www.todaysgeriatricmedicine.com, Marques et al. 2013, 
Bell et al. 2009). The vascular permeability of BBB in animal models can be 
analyzed by Evans Blue dye (EBD) assay (Jaffer et al. 2013, Manaenko et al. 
2011, Wang et al. 2014). Disruption of BBB is indicated by leakage of EBD into 
brain parenchyma (Wang et al. 2014).  
Evans Blue Dye (EBD) is a non-toxic, azo dye that binds to serum albumin 
promptly after being injected intravenously into the bloodstream, and functions as 
a fluorescent marker of serum albumin (Jaffer et al. 2013, Radu et al. 2013, 
Rákos et al. 2007, Wang et al. 2014). Since brain endothelium is impervious to 
albumin (Radu et al. 2013), serum albumin is unable to cross blood brain barrier 
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restricting EBD to blood vessels under normal state (Jaffer et al. 2013, Radu et 
al. 2013, Manaenko et al. 2011). However, during pathological conditions, the 
endothelium becomes porous allowing extravasation of EBD bound to albumin in 
the vascularized tissues (Radu et al. 2013, Rákos et al. 2007). Since the BBB is 
disarticulating in neurological diseases, in mice suffering from AD, EBD will be 
more in the brain tissues. EBD fluoresces with excitation peaks at 520 nm and 
emission peaks at 680 nm. The level of vascular permeability can be assessed 
by detecting the presence of blue color due to EB fluorescence in the tissues.  
 
Figure 3: Blood brain barrier 
The blood brain barrier is made up of endothelial cells connected by tight 
junctions, basal lamina and astrocytes.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Reagents and Antibodies 
The standard reagents were purchased from Sigma (St. Louis, MO). The 
PCR primers were bought from Invitrogen (Carlsband, CA). The TrizolTM 
reagent was bought from Invitrogen (Carlsband, CA). ELISA kits for S100 
Calcium Binding Protein B were obtained from Cloud-Clone Corp (Houston, TX). 
Evans Blue dye (Lot # MKBX1555V) was purchased from Sigma (St. Louis, MO). 
2.2 Ethical statement 
All animals used were maintained at the University of Central Florida 
vivarium accredited by Association for Assessment and Accreditation of 
Laboratory Animal Care International (AAALAC). All the protocols were in 
compliance with University of Central Florida Institutional Animal Care and Use 
Committee (IACUC) and followed the NIH guidelines.  
2.3 Animal models and development of strains 
Animal experiments were performed on 14 months old C57BL/6J mice, 
and 4 months and 14 months old ApoE-PON1 double knockout (DKO) mice. The 
C57BL/6J mice were used as controls. All mice analyzed in the study were of 
C57BL/6J background. Mice were purchased from Jackson laboratories. ApoE-
PON1 double knockout mice were developed by crossing ApoE knockout and 
PON1 knockout mice for 12 generations. The mice were genotyped by 
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polymerase chain reaction (PCR) of tail DNA and agarose gel electrophoresis 
following the instructions in supplier’s protocol (QIAGEN DNeasy Blood and 
Tissue Kit). 
2.4 Plasma lipid profile 
6 animals each of 14 months old C57BL/6J mice, 4 months and 14 
months old ApoE-PON1 DKO mice were fasted overnight and anesthetized with 
isoflurane (1-2% inhaled) the following day. Fasting blood samples were 
collected by heart puncture. Red Blood Cells and plasma was separated by 
centrifugation (3000 rpm for 20 minutes). Plasma lipid profiles of TRG 
(triglyceride), TC (total cholesterol), HDL-c (high density lipoprotein-cholesterol), 
LDL-c (low density lipoprotein-cholesterol) and vLDL-c (very low density 
lipoprotein-cholesterol) were determined using a Cholestec L*D*X analyzer 
(Cholestec Corp, Hayaward, CA). 
2.5 Analysis of lesions 
The aorta of 6 animals each of 14 months old C57BL/6J mice, 4 months 
and 14 months old ApoE-PON1 DKO mice were washed with cold Phosphate 
Buffer Solution (PBS) through the left ventricle. The aortas were dissected from 
iliac bifurcation to heart including beginning of carotid and subclavian arteries 
under a stereomicroscope. Excess fat and connective tissues were removed. 
Images of aorta were taken using digital camera and the lesions were marked 
under the microscope. Size of the atherosclerotic lesions were analyzed by the 
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software Image J. Rulers were used to mark out the pixel to mm2 conversion 
factor.  
2.6 Isolation of brain 
14 months old C57BL/6J mice, 4 months and 14 months old ApoE-PON1 
DKO mice were fasted overnight and anesthetized with 1-2% isoflurane. Blood 
samples were collected in vacutainer tubes by heart puncture. The blood was 
centrifuged at 3000 rpm for 20 minutes. Serum was separated and stored at 
80ºC. Brains were collected by opening the cranium, washed with saline and 
weighed. Few samples were stored in 4% paraformaldehyde to be used in 
histology and rest were snap frozen in liquid nitrogen for RNA isolation and gene 
expression studies.  
2.7 Histological analysis 
Brain samples were fixed in 4% paraformaldehyde. The tissues were 
processed and embedded with paraffin in blocks. 5-10 µm sections were cut 
using rotary microtome (Leica). The sections were stained with Hematoxylin and 
Eosin stain and 4G8 immunostaining. Images were taken using a Leica DM2000 
microscope using 5X, 10X and 40X objectives.  
2.7.1 Hematoxylin and Eosin staining 
The Hematoxylin and Eosin staining of the slides were done in the 
pathology core laboratory of The Children’s Hospital of Philadelphia Research 
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Institute, Philadelphia, PA and Sanford Burnham Prebys Medical Discovery 
Institute, Orlando, FL. The cells were quantified by the software Stereologer 
2000. 
2.7.2 4G8 immunostaining 
The 4G8 immunostaining for amyloid beta plaques of the slides were done 
in the pathology core laboratory of The Children’s Hospital of Philadelphia 
Research Institute, Philadelphia, PA. 
2.8 Isolation of RNA 
Isolation of RNA from mice brains was performed using TrizolTM reagent 
(Invitrogen #15596018). 800 µL Trizol reagent was added to the brain samples in 
tubes kept on ice. The tissue was homogenized using tissue homogenizer 
(PowerGen700) and transferred to a 1.5 ml Eppendorf tube. 160 µL of chloroform 
was added to the tubes and vigorously shaken for 10-15 seconds. The tubes 
were then centrifuged at 12,400 x g for 15 minutes at 4ºC. The aqueous phase 
was pipetted out and transferred to a new 1.5 ml eppendorf tube. The lower 
organic phase was stored in -80ºC for protein isolation. For precipitating RNA, 
400 µL of 100% isopropanol was added to the aqueous phase and incubated at 
room temperature for 10 minutes. The tubes were centrifuged at 12,000 x g for 
10 minutes at 4ºC and kept on ice for 10 minutes. The supernatant was aspirated 
and the tubes were air dried. Excess liquid was removed by capillary action with 
the help of pipette tips. To the RNA pellet, 1 ml of 75% ethanol was added. This 
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is the washing step. The sample was mixed gently and centrifuged at 7,400 x g 
for 5 minutes at 4ºC. The tubes with RNA were air dried for 10 minutes and 
resuspended in 50 µL of RNase free water. The concentration of RNA was 
determined using nanodrop instrument (Nanodrop 8000 spectrophotometer, 
Thermo Scientific) and calculated to use 1 µg of RNA for cDNA synthesis.  
2.9 cDNA synthesis 
Synthesis of cDNA by reverse transcription was performed using 
SuperScript III First-Strand Synthesis SuperMix for qRT-PCR kit from Invitrogen 
(Life Technologies #11752-050). The reagents were thawed and mixed well. The 
master mix was prepared in an eppendorf tube on ice by using the following kit 
components. 
Table 4: cDNA synthesis mix preparation. 
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The RT Enzyme Mix constitutes of SuperScript III RT and RNaseOUT. 2X 
RT Reaction Mix comprises of oligo(dT)20(2.5 µM), random hexamers (2.5 ng/ 
µL), 10 mM MgCl2, and dNTPs. The contents of the microcentrifuge tubes were 
mixed gently and incubated in a thermos cycler (Bioer Gene Pro Thermal 
Cycler/VWR) at 25ºC for 10 minutes and again at 50ºC for 30 minutes. The 
reaction was terminated by incubation at 85ºC for 5 mins. The samples were kept 
on ice for 5 minutes. 1 µL (2 U) of E.coli RNase H was added to the tubes and 
further incubated for 20 minutes at 37ºC. The samples were stored in -20ºC until 
future use. 
2.10 Real-Time PCR 
Quantitative Real-Time PCR was set up using SYBR Green ER qPCR 
SuperMix for iCycler (Invitrogen, Carlsbad, CA # 11761-500). The RT-PCR run 
was performed in Bio-Rad iQ5 Multicolor Real-Time PCR Detection System 
using a 96 well PCR plate (Bio-Rad #2239441). For each gene analyzed, a 
master mix was prepared using the following components. 
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Table 5: PCR components master mix preparation. 
 
19 µL of master mix was loaded in each well of PCR plate and 1 µL of 
cDNA was added. The plate was sealed with a microseal optical adhesive film 
(Bio-Rad#MSB1001) and centrifuged at 12,000 rpm for 10 minutes at 4ºC. The 
PCR plate was placed in a CFX 96 iCycler Multicolor Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA). Specific primers were used. GAPDH primers 
were used as reference. PCR was programmed for 1 cycle of 50ºC for 2 minutes 
followed by 1 cycle of 95ºC for 10 minutes. This was followed by 40 cycles of 
95ºC for 20 seconds each and 20 seconds at 60ºC. Melt curves were generated 
for the reactions at 95ºC for 1 minute, 55ºC for 1 minute and 80 cycles of 55ºC + 
0.5 ºC /cycle for 10 seconds till the temperature reached 95ºC. The Ct values 
and melt curves were analyzed using Iq5 Optical System Software provided by 
Bio-Rad. By using 2-ΔΔCt method, normalized fold expression was determined. 
The following primers for mouse targets were used: 
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Table 6: Primer sequences for Real-Time PCR. 
 
The mRNA levels were normalized corresponding to GAPDH gene 
expression levels. 
2.11 Enzyme Linked Immunosorbent Assay (ELISA) for S100B 
ELISA for S100B (Commercially available kits, Cloud-Clone Corp. 
Houston, TX) was carried out on blood samples collected from 8 mice each of 14 
months old C57BL/6J, 4 months old and 14 months old ApoE-PON1 DKO mice 
according to the supplier’s protocol. Optical density was measured at 450 nm by 
a microplate reader (Bio-Rad, Hercules, CA). Correction absorbance was 
measured at 540 nm. S100B levels were determined using Standard curves 
which were generated using Sigma plot and concentration of samples were 
determined from them. 
2.12 Evans Blue Dye perfusion 
5µg of Evans Blue dye solution was prepared by dissolving it in 1ml of 
sterile phosphate buffer solution and sterilized by passage through 0.22µm filter 
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(Fisherbrand Cat# 097203 22µm, PVDF sterile filter, Pittsburgh, PA). 100 µl of 
the dye was injected intravenously through the tail of 3 numbers each of 4 
months old C57BL/6J and ApoE-PON1 DKO mice and 14 months old ApoE-
PON1 DKO mice placed in a restraint device. The dye was allowed to circulate 
for 2 hours. After 2 hours the brain tissues were harvested. The intensity of the of 
the dye was evaluated by taking Fluorescence image using excitation 
wavelength 520nm and emission of 680 nm long pass filter. Fluorescence image 
of the brains were taken with 2 seconds exposure time and Reflectance image of 
brains were taken with 0.5 sec exposure time. Fluorescence and Reflectance ex-
vivo images were taken in Bruker Xtreme in-vivo machine overlayed using Bruker 
MI software. 
2.13 Statistical Analysis 
The results were expressed as mean + SD. Comparisons using paired or 
unpaired Student’s t-test and two-way ANOVA followed by Student’s t-test within 
groups were made between two or more than two groups. Statistical significance 
was assessed by Student’s t-test and differences with p< 0.05 were considered 
significant.   
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CHAPTER 3: RESULTS 
3.1 Weight of the animals 
An increase in the body weight of older ApoE-PON1 DKO mice (14 
months old) were observed compared to younger ApoE-PON1 DKO mice (4 
months old) and older controls C57BL/6J (14 months old) as shown in Figure 4. 
Apolipoprotein E is involved in lipid metabolism. Therefore, lack of ApoE would 
reduce the clearance of triglyceride from the body and result in increased body 
weight as seen in older ApoE-PON1 DKO mice.  
 
Figure 4: Average weight of animals in grams. 
Average weight of 14 months old C57BL/6J, 4 months and 14 months old ApoE-
PON1 DKO mice. The weight of older ApoE-PON1 DKO mice were significantly 
higher than age matched C57BL/6J mice and young ApoE-PON1 DKO mice. p 
value is less than 0.01. Values are represented as mean + SD. Differences with 
p<0.05 were accepted significant. 
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3.2 Plasma lipid profile 
A significant increase in the levels of triglycerides (TRG), total cholesterol 
(TC), Low density lipoprotein (LDL-c) and very Low Density Lipoprotein (vLDL-c) 
was observed in both young (4 months old) and old (14 months old) ApoE-PON1 
DKO mice compared to older (14 months old) controls C57BL/6J (Figure 5B). 
The increase in total cholesterol level was due to deficiency in Apolipoprotein E. 
The plasma sample of the control mice was transparent compared to the younger 
and older ApoE-PON1 DKO mice as seen in Figure 5A. The turbidity of the 
plasma is due to the increased level of TRG, TC and LDL.  
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Figure 5: Plasma samples and Plasma Lipid profiles 
Representation of the plasma samples of C57BL/6J, 4 months and 14 months 
old ApoE-PON1 DKO mice. The plasma of ApoE-PON1 DKO mice were more 
turbid than C57BL/6J mice due to lack of ApoE which led to increase in TRG, TC 
and LDL levels (A). Plasma lipid levels of 14 months old C57BL/6J, 4 months and 
14 months old ApoE-PON1 DKO mice. Values are represented as mean + SD. 
Differences with p<0.05 were accepted significant (B).  
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3.3 Weight of the brains 
The brains of the older ApoE-PON1 DKO mice (14 months old) had 
shrinkage. There was lack of blood in supply in the brains due to lesions in the 
carotid arteries. No differences in the weights of older (14 months old) control 
C57BL/6J mice and younger (4 months old) ApoE-PON1 DKO mice were 
observed (Figure 6B). The brain weight of older ApoE-PON1 DKO mice were 
significantly lower than the control and younger ApoE-PON1 DKO mice (Figure 
6B) because in Alzheimer’s brain there is death of neurons and degeneration of 
neuronal tissue.  
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Figure 6: Images and average weight of the brains. 
Representation of the brain samples of 14 months old C57BL/6J, 4 months and 
14 months old ApoE-PON1 DKO mice (A). The brain weights of 4 months old 
ApoE-PON1 DKO mice and 14 months old ApoE-PON1 DKO mice were 
significantly lower than the control C57BL/6J mice (B). The values are 
represented as mean + SD. Differences with p<0.05 were accepted significant.  
3.4 Analysis of lesions 
Atherosclerosis was examined in the older (14 months old) control 
C57BL/6J mice and older ApoE-PON1 DKO mice (14 months old) as well as 
younger ApoE-PON1 DKO mice (4 months old). The extent of lesions was 
documented by measuring the lesion surface area. As shown in Figure 7A, older 
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ApoE-PON1 DKO mice had more atherosclerotic lesions compared to younger 
ApoE-PON1 DKO mice and older control C57BL/6J mice. The increase in lesions 
suggest that atherosclerotic burden increased with age even on normal chow 
diet.  
 
 
Figure 7: Atherosclerotic lesions. 
Representative aortic lesions of 14 months old C57BL/6J, 4 months and 14 
months old ApoE-PON1 DKO mice (A). Lesion area quantified by Image J. The 
14 months old ApoE-PON1 DKO mice had significantly higher atherosclerotic 
lesions compared to age matched control C57BL/6J mice and 4 months old 
ApoE-PON1 DKO mice (B). The values are expressed as mean + SD. 
Differences with p<0.05 were accepted significant. 
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3.5 Histological analysis 
Histological examination reveals the evidence of the characteristic 
hallmarks of AD and helps in diagnosis of AD by identification of morphological 
abnormalities. Our main area of interest is the hippocampal region of the brain. 
Tissue sections were stained with Hematoxylin and Eosin (H and E) stain and 
4G8 immunostain. Hematoxylin stains blue/violet. It stains basic/ +ve in nucleus, 
binds DNA/RNA that are -vely charged and acidic. Eosin stains pink. It stains 
acidic/ -ve, binds proteins in cytoplasm. 4G8 is a primary mouse monoclonal 
antibody to Aβ. It illustrates central core and peripheral amyloid halo of plaque 
in brown. Histologically, the brains showed the following differences. 
In the H and E stained slides we see that the 14 months old ApoE-PON1 
DKO mice has disorganized granule cells, neuronal loss, loss of pyramidal cells 
and granule cells (Figure 8). Quantitative analysis of the pyramidal and granule 
cells showed a decrease in the cell numbers in the older ApoE-PON1 DKO mice 
compared to age matched control C57BL/6J mice and younger ApoE-PON1 
DKO mice (Figure 9). Deeply stained nuclei and Hirano bodies were also 
observed in the brain tissues of older ApoE-PON1 DKO mice (Figure 10).  
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Figure 8: Hematoxylin and Eosin staining of pyramidal and granular cells (5X 
magnification). 
The images shown are from the hippocampal section of the mice stained with H 
and E staining. The arrows represent disorganized granule cells and loss of 
pyramidal cells in the 14 months old ApoE-PON1 DKO mice.  
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Figure 9: Number of pyramidal cells and granule cells.  
There is a decrease in the number of both pyramidal (A) and granule cells (B) in 
the 14 months old ApoE-PON1 DKO mice. 
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Figure 10: Hematoxylin and Eosin staining of Hirano bodies and deeply stained 
nuclei (40X magnification). 
The images shown are from the hippocampal section of the mice stained with H 
and E staining. The arrows show the presence of Hirano bodies and deeply 
stained nuclei in the 14 months old ApoE-PON1 DKO mice. 
In the 4G8 immunostained slides we see the presence of amyloid beta 
plaques in the hippocampal region of the 14 months old ApoE-PON1 DKO mice 
(Figure 11). 
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Figure 11: 4G8 Immunostaining. 
The images shown are from the hippocampal section of the mice stained with 
4G8 immunostain. The arrows show the presence of amyloid beta plaques in the 
14 months old ApoE-PON1 DKO mice. 
3.6 Gene expression of S100B and Amyloid Precursor Protein 
For the detection of AD biomarkers, brains were isolated from mice, 
different parts of the brain were identified and separated. Biomarkers were 
detected in hippocampus, which is the major part of brain that undergoes 
damage in AD and leads to disorientation and memory loss. S100B gene 
expression was elevated in the hippocampus region of older (14 months old) 
ApoE-PON1 DKO mice compared to age matched control C57BL/6J mice and 
younger (4 months old) ApoE-PON1 DKO suggesting that older ApoE-PON1 
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DKO mice has AD pathology (Figure 12). However, the difference between 
younger (4 months old) and the older control and DKO mice was not significant. 
 
Figure 12: Gene expression of S100B in control and double knockout (DKO) 
mice 
S100B mRNA levels in control and double knockout mice. RNA was harvested 
and analyzed. Fold expression was normalized by using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). The values are expressed as mean + SD. 
Differences with p<0.05 were accepted significant. 
3.7 Enzyme Linked Immunosorbent Assay (ELISA) 
Significant elevated levels of S100B in older (14 months old) ApoE-PON1 
DKO serum was observed compared to age matched control and younger (4 
months old) ApoE-PON1 DKO mice (Figure 13). 
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Figure 13: Serum levels of S100B in control and double knockout (DKO) mice. 
The serum levels of S100B in 14 months old ApoE-PON1 DKO mice were 
significantly higher than age matched control and 4 months old ApoE-PON1 DKO 
mice. The values are expressed as mean + SD. Differences with p<0.05 were 
accepted significant. 
3.8 Evans Blue Dye perfusion 
To evaluate the changes in vascular permeability in the brain of mice 
suffering from atherosclerosis, Evans Blue Dye was used to determine leakage 
of albumin fraction of blood into brain tissue. The intensity of the permeable color 
of the dye was evaluated by taking Fluorescence image using excitation 
wavelength 520 nm and emission of 680 nm long pass filter. Reflectance image 
of brain was taken with 0.1 sec exposure time. Fluorescence and Reflectance ex-
vivo images were taken in Bruker Xtreme in-vivo machine overlayed using Bruker 
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MI software. The presence of EBD (red color) in the brains of older DKO mouse 
(Figure 14) was observed suggesting BBB damage. 
 
Figure 14: Evans Blue Dye Perfusion 
The brain samples of C57BL/6J, 4 months and 14 months old ApoE-PON1 DKO 
mice (A); Fluorescence images of 14 months old C57BL/6J, 4 months and 14 
months old ApoE-PON1 DKO mice (B); Overlayed images of 14 months old 
C57BL/6J, 4 months and 14 months old ApoE-PON1 DKO mice (C).  
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CHAPTER 4: DISCUSSION 
Alzheimer’s disease (AD) is one of the leading causes of death worldwide 
accounting for more than 35 million cases. It is the 6th leading cause of death in 
the US only. Alzheimer’s disease is a major disease that not only affects the 
brain, but also other functions associated with it. At present, human Alzheimer’s 
has no treatment, although there are potential drugs or antibodies that target the 
amyloid beta (Aβ) plaques, one of the most important pathological hallmarks of 
AD. Moreover, because the histopathological changes associated with the 
disease are concealed within the brain, it becomes difficult to diagnose AD. 
There are no or very few markers for the diagnosis of AD, so there is an 
increased need to know the etiology of the disease. Both genetic and 
environmental factors are attributed to AD. Current evidence suggests 
Apolipoprotein allele (ApoE) might be genetically linked to the development of 
Alzheimer’s. ApoE gene polymorphism (ApoE4) has been implicated in late onset 
of Alzheimer’s disease (LOAD). ApoE forms high density lipoproteins (HDL) and 
binds and degrades Aβ plaques. However, due to its polymorphism, ApoE is 
unable to degrade Aβ, thus increasing its level in the brain. Yet, the disease 
cannot be just genetic because younger people are not generally affected by the 
disease, only older people aged 65 or more are affected. Hence, other factors 
might be associated with the disease. 
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Oxidative stress has been implicated in many diseases. Oxidative stress is 
a very generic term and could be the result of environmental, nutritional, and 
pharmacological factors. There is not any single oxidative stress, and no single 
antioxidant enzyme that controls the body’s redox potential.  
During our course of study on atherosclerosis, we developed 
Apolipoprotein E-Paraoxonase 1 double knockout (ApoE-PON1 DKO) mice. 
These mice, as shown in the results section had severe atherosclerosis in the 
carotid and innominate arteries with 70-80% stenosis and an increase in plasma 
lipid levels at an older age (14 months). Based on these observations, we 
predicted that there will be diminished blood flow into the brain and reduced 
oxygen supply. Research from cell culture in a variety of systems suggest that 
deprivation of nutrients together with oxidative stress result in cellular death. So, 
in AD, based on carotid atherosclerosis, we interpreted that there would be cell 
death and poor utilization of blood supply. Lack of ApoE increases the levels of 
triglycerides and total cholesterol in the blood. This results in an increased body 
weight of the older DKO mice.  
The lack of ApoE cautioned us that the ApoE-PON1 DKO mice might have 
specific abnormalities related to AD. The histopathology of mice Alzheimer’s can 
be only compared to humans on the factors that are reminiscent of Alzheimer’s 
pathology. Our results show aggregation of Aβ plaques in older mice as also 
seen in human Alzheimer patients. In contrast, the younger ApoE-PON1 DKO 
mice did not have any plaques. Our histology results also show loss of pyramidal 
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and granular cells in the hippocampal region of the brain, as well as presence of 
Hirano bodies and deeply stained nuclei, all of which are histological 
characteristics of AD.  
At present, S100B, tau proteins, C-reactive proteins, Amyloid Precursor 
Protein, Presinilin are known to be specific markers for AD. Our results show an 
increase in S100B gene expression in older ApoE-PON1 DKO mice compared to 
age matched control and younger ApoE-PON1 DKO mice. In general, S100B 
protein designates inflammatory changes. This suggests that Alzheimer’s or 
pathology seen in our animals also reflect highly elevated inflammatory 
response. This raises an important question, whether chronic inflammation 
contributes to Alzheimer’s disease. If so, whether those who are predisposed to 
Alzheimer’s for example, those who have defective ApoE allele, would require 
pharmacological agents and supplements that would reduce Alzheimer’s and 
reflect in delayed onset of Alzheimer’s or a progressive change from abnormal 
pathology to normal pathology could be only speculated. 
Disarticulation of the blood brain barrier (BBB) increases permeability of 
neurotoxic proteins and other proteins in the serum resulting in vascular 
dysfunction and cell death. Vascular permeability of the BBB can be assessed by 
the extravasation of Evans Blue Dye (EBD) in the brain parenchyma. As noted in 
our results, there is an increased distribution of EBD across the brain tissues of 
older ApoE-PON1 DKO mice, suggesting gross differences in permeability. This 
would suggest that nutrients or neurostimulators, and neurotoxins are going to be 
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distributed in the brain causing neuronal death and affecting the function of the 
brain.  
Phosphorylation and dephosphorylation reactions are very common in 
biology. They reflect the ongoing state of metabolic changes in our system. 
Whether these changes could be reversed has not yet been established. Also, if 
atherosclerosis of arteries is significant in inducing apoptotic changes in addition 
of phosphorylated proteins, then one can devise strategies to control 
atherosclerosis.  
Already nutritional and pharmacological means are available as regulators 
of atherosclerotic process. At present, they relate to two kinds of drugs, Statins, 
that specifically control cholesterol synthesis and PCSK9, which on the other 
hand decrease overall cellular metabolism of cholesterol. While statins and AD 
have been studied and there are confusing line of evidence whether statins could 
affect Alzheimer’s, the potential of PCSK9 antibodies to control AD have not 
been established. Future research as well as long term epidemiological changes 
are required on this account. 
Cholesterol, phospholipids, unsaturated fatty acids are all important 
components of the brain, particularly myelin sheath. These are all lipids that the 
brain utilizes for its structural integrity as well as functions. However, the 
contribution of dyslipidemia and cholesterol to AD appears to be questionable, as 
recent studies point out that very little Low Density Lipoprotein (LDL) is taken up 
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by neuronal tissues. This raises the question as to whether prevention of 
atherosclerosis or lowering plasma LDL would have a significant effect on AD. 
This will give us an opportunity to develop modulations in atherosclerosis that 
might lead to beneficial changes in neurological diseases. Also, it remains to be 
seen if the neurological symptoms could be reversed. Increase in cholesterol and 
triglyceride levels result in hypercholesterolemia, which induces Aβ secretion and 
also leads to atherosclerosis. 
If atherosclerosis or differences in Apo E lead to AD, there might be 
simpler ways of correcting it. So, one of the future questions of the study is to ask 
the question whether AD could be prevented by preventing atherosclerosis from 
early childhood. 
In this study, we demonstrated that animals that are deficient in 
apolipoprotein E with severe carotid stenosis demonstrate Alzheimer phenotype. 
However, the experiments do not delineate specific role of ApoE versus coronary 
occlusion. So, further experiments are needed using LDLR knockout mice, which 
is also an important model to study atherosclerosis to suggest specific role of 
ApoE or occlusion as opposed to nutrient deprivation.  
Paraoxonase 1 is synthesized in the liver and it circulates in the blood. 
The ability of PON1 to cross the blood brain barrier has not yet been determined. 
It is possible that localized factors are more important in causing oxidative stress 
in the brain. PON2, however is synthesized by brain tissues. Future experiments 
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involving PON2 knockout mice are needed to suggest the role of PON2 in 
oxidative stress in ApoE deficient atherosclerotic mice.  
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